7 Key Challenges Face Ebola Vaccine Developers, Stakeholders

The Lancet: Is the world ready for an Ebola vaccine?
Bruce Y. Lee of the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health and colleagues

“…We propose seven key challenges to be considered early in Ebola vaccine development that will help stakeholders prepare and allow developers to adjust vaccine characteristics accordingly. … The first challenge is who will be vaccinated and who will make this decision? … how will the vaccine reach the target population? … how the vaccine will be administered. … how safe does the vaccine need to be? … how the benefits and risks of an Ebola vaccine should be communicated to the public and major stakeholders. … how the vaccine would fit into affected countries’ existing fragile health systems. … [and] the cost of an Ebola vaccine and who will pay for it…” (1/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.